Working… Menu
Trial record 1 of 1 for:    NCT01619891
Previous Study | Return to List | Next Study

VitamIN D Treating patIents With Chronic heArT failurE (VINDICATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01619891
Recruitment Status : Completed
First Posted : June 14, 2012
Last Update Posted : October 26, 2016
Information provided by (Responsible Party):
KK Witte, University of Leeds

Brief Summary:
Despite recent advances and even when receiving optimal therapy, patients with chronic heart failure (CHF) suffer poor quality of life, with recurrent hospitalisations and persistent symptoms. The investigators have shown that patients attending the Leeds Integrated Heart Failure Service are also frequently deficient in vitamin D and that the severity of the deficiency relates to the levels of symptoms, exercise capacity, diuretic requirements and response to optimal medical therapy. Vitamin D contributes to cardiac and skeletal muscle contractile function, immune function, pancreatic insulin release, and neuro-hormonal homeostasis. A randomised, placebo-controlled proof of concept study in 60 CHF patients has demonstrated improvements in submaximal exercise capacity and symptoms. VINDICATE will be a randomised, placebo-controlled developmental clinical study in 250 patients with CHF and vitamin D deficiency. The present study is designed to detect whether vitamin D has pathophysiologically important effects, as well as providing preliminary evidence of efficacy and safety by examining cardiac function (using cardiac magnetic resonance imaging) and submaximal exercise capacity (by 6-minute walk test). This will provide pertinent data to inform a larger multi-centre efficacy and effectiveness study.

Condition or disease Intervention/treatment Phase
Chronic Heart Failure Dietary Supplement: Vitamin D Phase 2

Detailed Description:
This is a randomized placebo-controlled trial of vitamin D versus placebo in people with heart failure. Primary endpoint is 6 minute walk distance.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 253 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: VitamIN D Treating patIents With Chronic heArT failurE
Study Start Date : August 2012
Actual Primary Completion Date : October 2015
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Vitamin D

Arm Intervention/treatment
Active Comparator: Vitamin D
Vitamin D 100mcg per day
Dietary Supplement: Vitamin D
100mcg per day

Placebo Comparator: Placebo
Standard optimal therapy
Dietary Supplement: Vitamin D
100mcg per day

Primary Outcome Measures :
  1. 6 minute walk distance [ Time Frame: After one year ]

Secondary Outcome Measures :
  1. Left ventricular function by Cardiac Magnetic Resonance [ Time Frame: At one year ]
  2. Peak exercise capacity [ Time Frame: At one year ]
  3. Biochemical changes [ Time Frame: At one year (but also throughout) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Class II or III CHF
  • Stable symptoms (on otherwise optimally tolerated medical therapy)
  • Able to give written informed consent

Exclusion Criteria:

  • Currently taking vitamin D supplementation
  • Untreated valvular heart disease
  • Existing class I indication for vitamin D therapy
  • History of primary hyperparathyroidism, tuberculosis, sarcoidosis, malignancy or hypercalcaemia
  • Heart failure due to anaemia or thyrotoxicosis
  • Renal failure (GFR <30l/min)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01619891

Layout table for location information
United Kingdom
Leeds General Infirmary
Leeds, United Kingdom, LS1 3EX
Sponsors and Collaborators
University of Leeds
Layout table for investigator information
Principal Investigator: Klaus K Witte, MD University of Leeds
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: KK Witte, Senior Lecturer in Cardiology, University of Leeds Identifier: NCT01619891    
Other Study ID Numbers: MR/J00281X/1
First Posted: June 14, 2012    Key Record Dates
Last Update Posted: October 26, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Vitamin D
Physiological Effects of Drugs
Bone Density Conservation Agents